TIDL
TIDL is a pharmaceutical startup that offers next-generation pain relief solutions through innovative formulations and dosage forms. Their flagship product, the Cryotherapy Spray, has gained widespread popularity and success, breaking records in online sales and securing shelf space in major retail outlets in the U.S. and globally. The company's products have garnered trust from medical clinics, everyday consumers, and professional athletes, positioning TIDL as a leader in the pain relief industry.
Founded in 2019, TIDL operates primarily in the Manufacturing and Pharmaceutical industries, with a focus on creating effective products to alleviate various types of pain, including arthritis, nerve pain, sprains, and back pain. The brand's commitment to innovation and quality is evident in its use of new active ingredient combinations and plant-derived components that enhance application and eliminate unwanted odors associated with traditional pain relief products.
TIDL products have gained traction among pain specialists and professional athletes, with a strategic presence in sports rehab sections and rare topicals offered by major retailers due to their unique efficacy and high quality. The company's global availability in over 10 countries signifies its intent to expand further by the summer of 2023.
With a compelling mission to provide immediate relief and enable consumers to return to their normal activities without limitations, TIDL is dedicated to creating solutions that address the debilitating effects of pain that are often underserved by current over-the-counter options.
There is no investment information
No recent news or press coverage available for TIDL.